NeoGenomics (NEO) 10-Q 9 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 04, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	NEO
Entity Registrant Name	NEOGENOMICS INC
Entity Central Index Key	1,077,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		79,237,045

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 11,036	$ 12,525
Accounts receivable (net of allowance for doubtful accounts of $14,644 and $13,699, respectively)	61,718	55,512
Inventories	5,970	6,253
Other current assets	5,857	4,535
Total current assets	84,581	78,825
Property and equipment (net of accumulated depreciation of $31,012 and $27,102, respectively)	36,531	34,036
Intangible assets, net	75,339	77,064
Goodwill	147,019	147,019
Other assets	167	174
Total assets	343,637	337,118
Current liabilities
Accounts payable	20,579	16,782
Accrued compensation	7,697	8,351
Accrued expenses and other liabilities	2,766	4,247
Short-term portion of capital leases	4,997	4,891
Short-term portion of loans	3,837	3,842
Total current liabilities	39,876	38,113
Long-term liabilities
Long-term portion of capital leases	5,931	5,378
Long-term portion of loans, net	69,363	70,259
Revolving credit facility, net	26,860	21,799
Deferred income tax liability, net	7,583	14,973
Total long-term liabilities	109,737	112,409
Total liabilities	149,613	150,522
Commitments and contingencies - see Note I
Redeemable convertible preferred stock
Series A Redeemable Convertible Preferred Stock, $0.001 par value, (50,000,000 shares authorized; and 6,600,000 shares issued and outstanding, respectively)	25,439	22,873
Stockholders' equity
Common stock, $0.001 par value, (250,000,000 shares authorized; 79,206,945 and 78,571,158 shares issued and outstanding, respectively)	79	79
Additional paid-in capital	217,626	216,104
Accumulated deficit	(49,120)	(52,460)
Total stockholders’ equity	168,585	163,723
Total liabilities, redeemable convertible preferred stock and stockholders' equity	$ 343,637	$ 337,118

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 14,644	$ 13,699
Property and equipment, accumulated depreciation	$ 31,012	$ 27,102
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	79,206,945	78,571,158
Common stock, shares outstanding	79,206,945	78,571,158
Redeemable Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Redeemable Convertible Preferred Stock, shares authorized	50,000,000	50,000,000
Redeemable Convertible Preferred Stock, shares issued	6,600,000	6,600,000
Redeemable Convertible Preferred Stock, shares outstanding	6,600,000	6,600,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
NET REVENUE
Clinical testing	$ 56,690	$ 54,622
Pharma Services	4,986	5,082
Total Revenue	61,676	59,704
COST OF REVENUE	34,480	32,531
GROSS MARGIN	27,196	27,173
Operating expenses:
General and administrative	20,801	18,005
Research and development	862	1,446
Sales and marketing	5,648	5,800
Total operating expenses	27,311	25,251
INCOME (LOSS) FROM OPERATIONS	(115)	1,922
Interest expense, net	1,364	1,593
Income (loss) before taxes	(1,479)	329
Income tax (benefit) expense	(825)	174
NET INCOME (LOSS)	(654)	155
Deemed dividends on preferred stock	894	1,840
Amortization of preferred stock beneficial conversion feature	1,672	3,727
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (3,220)	$ (5,412)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.04)	$ (0.07)
Diluted	$ (0.04)	$ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	78,650	76,068
Diluted	78,650	76,068

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ (654)	$ 155
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	3,979	3,585
Amortization of intangibles	1,725	2,026
Amortization of debt issue costs	110	182
Stock based compensation – options, restricted stock and warrants	1,130	703
Provision for bad debts	3,783	2,663
Changes in assets and liabilities, net:
(Increase) in accounts receivable, net of write-offs	(9,989)	(3,809)
(Increase) decrease in inventories	283	(225)
(Increase) in prepaid expenses	(1,321)	(401)
Decrease in other current assets	6
Increase (decrease) in accounts payable and other liabilities	(738)	2,180
Net cash provided by (used in) operating activities	(1,686)	7,059
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(3,007)	(1,001)
Net cash used in investing activities	(3,007)	(1,001)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from revolving credit facility, net	5,006
Repayment to revolving credit facility		(10,044)
Repayment of capital lease obligations/loans	(1,263)	(1,372)
Repayment on term loan, net	(932)	(7)
Issuance of common stock for the exercise of options, warrants and ESPP shares	505	1,298
Payments of equity issue costs	(112)	(97)
Net cash provided by (used in) financing activities	3,204	(10,222)
Net change in cash and cash equivalents	(1,489)	(4,164)
Cash and cash equivalent, beginning of period	12,525	23,420
Cash and cash equivalents, end of period	11,036	19,256
Supplemental disclosure of cash flow information:
Interest paid	1,257	1,416
Income taxes paid	5	207
Supplemental disclosure of non-cash investing and financing information:
Equipment acquired under capital lease/loan obligations	1,898	173
Deemed dividends on preferred stock	894	1,840
Amortization of preferred stock beneficial conversion feature	$ 1,672	$ 3,727

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Note A – Nature of Business and Basis of Presentation NeoGenomics, Inc., a Nevada corporation (the “Parent”), and its subsidiaries, NeoGenomics Laboratories, Inc., a Florida corporation (“NEO” or, “NeoGenomics Laboratories”), NeoGenomics Bioinformatics Inc., a Florida corporation, Path Labs LLC., a Delaware limited liability company (“PathLogic”) and Clarient Inc., a Delaware corporation, and its wholly owned subsidiary Clarient Diagnostic Services, Inc. (together, “Clarient”), (collectively referred to as “we”, “us”, “our”, “NeoGenomics”, or the “Company”), operates as a certified “high complexity” clinical laboratory in accordance with the federal government’s Clinical Laboratory Improvement Act, as amended (“CLIA”), and is dedicated to the delivery of clinical diagnostic services to pathologists, oncologists, urologists, hospitals, and other laboratories throughout the United States. The accompanying interim consolidated financial statements are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. These accompanying interim consolidated financial statements include the accounts of the Parent and its subsidiaries. All intercompany transactions and balances have been eliminated in the accompanying interim consolidated financial statements. Certain information and footnote disclosures normally included in the Company’s annual audited consolidated financial statements and accompanying notes have been condensed or omitted in these accompanying interim consolidated financial statements. Accordingly, the accompanying interim consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 14, 2017. The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations that may be expected for any future periods. In the opinion of management, these unaudited consolidated financial statements include all adjustments and accruals, consisting only of normal recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein. We have one reportable operating segment that delivers testing services to hospitals, pathologists, oncologists, other clinicians, and researchers, which represents 100% of the Company’s consolidated assets, net revenues and net income (loss) for the three months ended March 31, 2017 and 2016. We have evaluated our segments based on how the Chief Operating Decision Maker (“CODM”), our Chief Executive Officer, reviews performance and makes decisions in managing the Company. At March 31, 2017, all of our services were provided within the United States and all of our assets were located in the United States. We have two primary types of customers, clinical and pharma. Our clinical customers include community based pathology practices, oncology groups, hospitals and academic centers. Our pharma customers include pharmaceutical companies to whom we provide testing and other services to support their studies and clinical trials. We continue to assess the information available to the CODM since the close of the Clarient acquisition. Currently, discrete financial information is not available to the CODM about the separate financial performance of our clinical and our pharma customers. As we continue to integrate the two companies and focus separately on the two customer types we will routinely assess the information available and reviewed by the CODM and determine if we meet the criteria for having separate segments.

Recently Adopted and Issued Acc

Recently Adopted and Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2017
Accounting Changes And Error Corrections [Abstract]
Recently Adopted and Issued Accounting Guidance	Note B — Recently Adopted and Issued Accounting Guidance Adopted In March 2016, the Financial Accounting Standards Board Accounting Standards Update (“A No. 2016-09, Improvements to Employee Share-Based Payment Accounting. The standard update requires excess tax benefits and tax deficiencies to be recorded directly through earnings as a component of income tax expense. Under current GAAP, these differences are generally recorded in additional paid-in capital and thus have no impact on net income. The change will also impact the computation of diluted earnings per share, and the cash flows associated with those items will be classified as operating activities on the condensed statements of consolidated cash flows. Entities will be permitted to make an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards. Forfeitures can be estimated, as required under current GAAP, or recognized when they occur. The Company adopted this ASU on January 1, 2017 using the transition method prescribed for each applicable provision: • Based on the implementation guidance, previously unrecognized excess tax benefits should be recognized on a modified retrospective basis beginning in the period the guidance is adopted. Accordingly, the Company recorded an increase in deferred tax assets and an offsetting cumulative-effect adjustment to retained earnings of $6.6 million as of January 1, 2017 for excess tax benefits not previously recognized. • Based on the implementation guidance, all excess tax benefits and tax deficiencies related to share based compensation will be reported in net income (loss) on a prospective basis. • The Company has elected to retrospectively adopt the requirement to present cash flows related to excess tax benefits as cash flows from operating activities. This adoption had no effect on cash flows for the three months ended March 31, 2016. • The Company has elected to recognize forfeitures in compensation cost as they occur. Issued In January 2017, the FASB issued ASU No. 2017-01, Business Combinations In January 2017 the FASB issued ASU No. 2017-04, Intangibles – Goodwill and Other: Simplifying the Test for Goodwill Impairment In August 2016, the FASB issued “ASU” 2016-15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments In February 2016, the FASB issued ASU No. 2016-02, Leases. The update requires ASU 2016-02 is effective for periods beginning after December 15, 2018 and interim periods within those periods. In May 2014, the FASB issued ASU 2014-09, Revenues from Contracts with Customers The Company expects to adopt this ASU in the first quarter of 2018 using a full retrospective method of adoption. We anticipate enhanced financial statement disclosures surrounding the nature, amount, timing and uncertainty of revenue and cash flows. While we continue to assess the impact of the adoption of this standard, we do not expect that it will have a material impact on our consolidated financial statements.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Note C — Goodwill and Intangible Assets The Company has recorded goodwill of $147.0 million as of March 31, 2017. The changes in the carrying amount of goodwill for the three month period ended March 31, 2017 and for the year ended December 31, 2016 are as follows (in thousands): March 31, December 31, 2017 2016 Balance as of January 1 $ 147,019 $ 147,019 Goodwill acquired during the period - - Balance at end of period $ 147,019 $ 147,019 Intangible assets as of March 31, 2017 and December 31, 2016 consisted of the following (in thousands): March 31, 2017 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 1,883 $ 1,117 Customer Relationships 156 - 180 months 81,000 6,778 74,222 Total $ 84,000 $ 8,661 $ 75,339 December 31, 2016 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 1,508 $ 1,492 Customer Relationships 156 - 180 months 81,000 5,428 75,572 Total $ 84,000 $ 6,936 $ 77,064 We recorded approximately $1.7 and $2.0 million in straight-line amortization expense of intangible assets for the three months ended March 31, 2017 and 2016, respectively. The Company recorded amortization expense from customer relationships and trade names as a general and administrative expense. The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2017 is as follows (in thousands): Year Ending March 31, Remainder of 2017 $ 5,167 2018 5,400 2019 5,400 2020 5,400 2021 5,400 Thereafter 48,572 Total $ 75,339

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt	Note D — Debt The following table summarizes the long term debt at March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 December 31, 2016 Term Loan Facility $ 74,063 $ 75,000 Revolving Credit Facility 27,900 22,900 Capital leases/loans 11,105 10,471 Total Debt 113,068 108,371 Less: Debt issuance costs (2,080 ) (2,202 ) Less: Current portion of long-term debt (8,834 ) (8,733 ) Total Long-Term Debt, net $ 102,154 $ 97,436 The carrying value of the Company’s long-term capital lease obligations and term debt approximates its fair value based on the current market conditions for similar instruments. Term Loan On December 22, 2016, the Company entered into a Credit Agreement with Regions Bank as administrative agent and collateral agent. The Credit Agreement provided for a $75.0 million term loan facility (the “Term Loan Facility”). The Credit Agreement also provides incremental facility capacity of $50 million, subject to certain conditions . The Term Loan Facility bears interest at a rate per annum equal to an applicable margin plus, at NeoGenomics Laboratories’ option, either (1) the Adjusted LIBOR rate for the relevant interest period, (2) an alternate base rate determined by reference to the greatest of (a) the prime lending rate of Regions, (b) the federal funds rate for the relevant interest period plus 0.5% per annum and (c) the one month LIBOR rate plus 1% per annum, or (3) a combination of (1) and (2). The applicable margin will range from 2.25% to 3.50% for LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories’ consolidated leverage ratio (as defined in the Credit Agreement). Interest on borrowings under the Revolving Credit Facility is payable on the last day of each month, in the case of each base rate loan, and on the last day of each interest period (but no less frequently than every three months), in the case of Adjusted LIBOR loans. The Company entered into an interest rate swap agreement to hedge against changes in the variable rate of a portion of this debt. See Note E-Derivative Instruments and Hedging Activities for more information on this instrument. The Term Loan Facility and amounts borrowed under the Revolving Credit Facility are secured on a first priority basis by a security interest in substantially all of the tangible and intangible assets of NeoGenomics Laboratories and the Guarantors. The Term Loan Facility contains various affirmative and negative covenants including ability to incur liens and encumbrances; make certain restricted payments, including paying dividends on its equity securities or payments to redeem, repurchase or retire its equity securities; enter into certain restrictive agreements; make investments, loans and acquisitions; merge or consolidate with any other person; dispose of assets; enter into sale and leaseback transactions; engage in transactions with its affiliates, and materially alter the business it conducts. In addition, the Company must meet certain maximum leverage ratios and fixed charge coverage ratios as of the end of each fiscal quarter commencing with the quarter ending March 31, 2017. The Company was in compliance with all required covenants as of March 31, 2017. The Term Loan Facility has a maturity date of December 21, 2021. The Credit Agreement requires NeoGenomics Laboratories to mandatorily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility with (i) 100% of net cash proceeds from certain sales and dispositions, subject to certain reinvestment rights, (ii) 100% of net cash proceeds from certain issuances or incurrences of additional debt, (iii) beginning with the fiscal year ending December 31, 2017, 50% of excess cash flow (as defined), subject to a step down to 0% of excess cash flow if NeoGenomics Laboratories’ consolidated leverage ratio is no greater than 2.75:1.0 and (iv) 100% of net cash proceeds from issuances of permitted equity securities by NeoGenomics Laboratories made in order to cure a failure to comply with the financial covenants. NeoGenomics Laboratories is permitted to voluntarily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility at any time without penalty. Auto Loans The Company has auto loans with various financial institutions. The auto loan terms range from 36-60 months and carry interest rates from 0.0% to 5.2%. Capital Leases The Company has entered into capital leases to purchase laboratory and office equipment. These leases expire at various dates through 2020 and the weighted average interest rate under such leases was approximately 5.64% at March 31, 2017. Most of these leases contain bargain purchase options that allow us to purchase the leased property for a minimal amount upon the expiration of the lease term. The remaining leases have purchase options at fair market value. Property and equipment acquired under capital lease agreements are pledged as collateral to secure the performance of the future minimum lease payments. Revolving Credit Facility On December 22, 2016, the Company entered into a Credit Agreement with Regions Bank as administrative agent and collateral agent. The Credit Agreement provided for a $75.0 million revolving credit facility (the “Revolving Facility”). On March 31, 2017, and December 31, 2016, the Company had outstanding borrowings of approximately $26.9 and $21.8 million, net of unamortized debt issuance costs of $1.0 and $1.1 million, respectively. The Revolving Credit Facility includes a $10 million swingline sublimit, with swingline loans bearing interest at the alternate base rate plus the applicable margin. Any principal outstanding under the Revolving Credit Facility is due and payable on December 21, 2021 or such earlier date as the obligations under the Credit Agreement become due and payable pursuant to the terms of the Credit Agreement. The Revolving Facility bears interest at a rate per annum equal to an applicable margin plus, at NeoGenomics Laboratories’ option, either (1) the Adjusted LIBOR rate for the relevant interest period, (2) an alternate base rate determined by reference to the greatest of (a) the prime lending rate of Regions, (b) the federal funds rate for the relevant interest period plus 0.5% per annum and (c) the one month LIBOR rate plus 1% per annum, or (3) a combination of (1) and (2). The applicable margin will range from 2.25% to 3.50% for Adjusted LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories’ consolidated leverage ratio. Interest on the outstanding principal of the Term Loan Facility will be payable on the last day of each month, in the case of each base rate loan, and on the last day of each interest period (but no less frequently than every three months), in the case of LIBOR loans. The Credit Agreement requires NeoGenomics Laboratories to mandatorily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility with (i) 100% of net cash proceeds from certain sales and dispositions, subject to certain reinvestment rights, (ii) 100% of net cash proceeds from certain issuances or incurrences of additional debt, (iii) beginning with the fiscal year ending December 31, 2017, 50% of excess cash flow (minus certain specified other payments), subject to a step down to 0% of excess cash flow if NeoGenomics Laboratories’ consolidated leverage ratio is no greater than 2.75:1.0 and (iv) 100% of net cash proceeds from issuances of permitted equity securities by NeoGenomics Laboratories made in order to cure a failure to comply with the financial covenants. NeoGenomics Laboratories is permitted to voluntarily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility at any time without penalty, subject to customary “breakage” costs with respect to prepayments of Adjusted LIBOR rate loans made on a day other than the last day of any applicable interest period. Maturities of Long-Term Debt Maturities of long-term debt at March 31, 2017 are summarized as follows (in thousands): Debt Capital Lease Obligations and Car Loans Total Long Term Debt Remainder of 2017 $ 2,812 $ 5,922 $ 8,734 2018 3,750 4,362 8,112 2019 5,625 2,764 8,389 2020 5,625 335 5,960 2021 84,151 - 84,151 101,963 13,383 115,346 Less: Interest on capital leases - (2,278 ) (2,278 ) 101,963 11,105 113,068 Less: Current portion of long-term debt (3,750 ) (5,084 ) (8,834 ) Less: Debt issuance costs (2,080 ) - (2,080 ) Long-term debt, net $ 96,133 $ 6,021 $ 102,154

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	3 Months Ended
	Mar. 31, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	Note E – Derivative Instruments and Hedging Activities Cash Flow Hedges In December of 2016, the Company entered into an interest rate swap agreement to reduce our exposure to interest rate fluctuations on our variable rate debt obligations. This derivative financial instrument is accounted for at fair value as a cash flow hedge which effectively modifies our exposure to interest rate risk by converting a portion of our floating rate debt to a fixed rate obligation, thus reducing the impact of interest rate changes on future interest expense. We account for derivatives in accordance with FASB ASC Topic 815, see Note B-Summary of Significant Accounting Policies in Annual Report on Form 10-K for more information on our accounting policy related to derivative instruments and hedging activities. Under this agreement, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest at 1.59%. The interest rate swap agreement was effective as of December 30, 2016 and a termination date of December 31, 2019. As of March 31, 2017 and December 31, 2016, the total notional amount of the Company’s interest rate swaps were $50 million. The fair value of the interest rate swap will be included in other long term assets or liabilities, when applicable. As of March 31, 2017 and December 31, 2016, the fair value of the interest rate swap was not considered to be significant due to the change in LIBOR over that time period outstanding, therefore, no amount is included on the balance sheet for this instrument. As the specific terms and notional amounts of the derivative financial instrument match those of the fixed-rate debt being hedged, the derivative instruments are assumed to be perfectly effective hedges and accordingly, there is no impact to the Company's consolidated statements of operations. Gains and losses on this interest rate swap agreement will be recorded in accumulated other comprehensive income and will be reclassified to interest expense in the period during which the hedged transaction affects earnings. At March 31, 2017 and December 31, 2016, there was no impact to accumulated other comprehensive income (AOCI) as it was determined that there was not a significant change to record. The fair value of this instrument will be evaluated on a quarterly basis and adjusted as necessary.

Class A Redeemable Convertible

Class A Redeemable Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2017
Temporary Equity Disclosure [Abstract]
Class A Redeemable Convertible Preferred Stock	Note F — Class A Redeemable Convertible Preferred Stock On December 30, 2015, NeoGenomics issued 14,666,667 shares of its Series A Preferred stock as part of the consideration for the acquisition of Clarient. The Series A Preferred Stock has a face value of $7.50 per share for a total liquidation value of $110 million. During the first year, the Series A Preferred Stock had a liquidation value of $100 million if the shares were redeemed prior to December 29, 2016. On December 22, 2016, the Company redeemed 8,066,667 shares of the Series A Preferred Stock for $55.0 million in cash. The redemption amount per share equaled $6.8181825 ($7.50 minus the liquidation discount of 9.0909%). At March 31, 2017, 6,600,000 shares of Series A Preferred Stock were outstanding. The carrying amount of the Series A Preferred Stock at March 31, 2017 was $25,439 million as compared to the carrying amount at December 31, 2016 of $22,873 million. The increase in the carrying amount is from the accrual of deemed dividends of approximately $894,000 and the accretion of the beneficial conversion feature of approximately $1.7 million during the three months ending March 31, 2017, of which both amounts are recorded as distributions to the holders of the Series A Preferred Stock on the income statement with the corresponding entry recorded as an increase to the carrying value of the Series A Preferred Stock. Issue Discount The Company recorded the Series A Preferred Stock at a fair value of approximately $73.2 million or $4.99 per share on the date of issuance. The difference between the fair value of $73.2 million and the liquidation value of $110 million represents a discount of $36.8 million from the initial face value as a result of assessing the impact the rights and features of the instrument and their effect on the value to the Company. After redemption, the Series A Preferred stock has a fair value of approximately $32,940 or $4.99 per share. The difference between the fair value of $32,940 and the liquidation value of $49,500 represents a discount of $16,560. Beneficial Conversion Features The fair value of the common stock into which the Series A Preferred Stock is convertible exceeded the allocated purchase price fair value of the Series A Preferred Stock at the date of issuance and after redemption by approximately $44.7 and $20.1 million, respectively, resulting in a beneficial conversion feature. The Company will recognize the beneficial conversion feature as non-cash, deemed dividend to the holder of Series A Preferred Stock over the first three years the Series A Preferred Stock is outstanding, as the date the stock first becomes convertible is three years from the issue date. The amount recognized for the three months ended March 31, 2017 was approximately $1.7 million. In addition to the beneficial conversion feature (“BCF”) recorded at the original issue date, we recorded additional BCF discounts for payment-in-kind shares accrued for the quarter ended March 31, 2017, as dividends. After the early redemption, the face value of the remaining Series A Preferred Stock is $49.5 million. We will issue 264,000 additional shares ($49.5 million * 4.0%) / $7.50) of Series A Preferred Stock as payment-in-kind dividends for the year ending December 31, 2017, the first year dividends are payable. The additional 264,000 shares will be discounted and amortized to the income statement over the remaining period up to the earliest conversion date, which is three years from the original issue date. The additional BCF discount recorded at March 31, 2017 was approximately $201,000. Automatic Conversion Each share of Series A Preferred Stock issued and outstanding as of the tenth anniversary of the original issue date will automatically convert into fully paid and non-assessable shares of common stock. Classification The Company classified the Series A Preferred Stock as temporary equity on the consolidated balance sheets due to certain change in control events that are outside the Company’s control, including deemed liquidation events described in the Series A Certificate of Designation.

Revenue Recognition and Contrac

Revenue Recognition and Contractual Adjustments	3 Months Ended
	Mar. 31, 2017
Revenue Recognition [Abstract]
Revenue Recognition and Contractual Adjustments	Note G — Revenue Recognition and Contractual Adjustments The Company recognizes revenues when (a) the price is fixed or determinable, (b) persuasive evidence of an arrangement exists, (c) the service is performed and (d) collectability of the resulting receivable is reasonably assured. The Company’s specialized diagnostic services are performed based on a written test requisition form or electronic equivalent, and revenues are recognized once the diagnostic services have been performed, and the results have been delivered to the ordering physician. These diagnostic services are billed to various payers, including Medicare, commercial insurance companies, other directly billed healthcare institutions such as hospitals and clinics, and individuals. The Company reports revenues from contracted payers, including Medicare, certain insurance companies and certain healthcare institutions, based on the contractual rate, or in the case of Medicare, published fee schedules. The Company reports revenues from non-contracted payers, including certain insurance companies and individuals, based on the amount expected to be collected. The difference between the amount billed and the amount estimated to be collected from non-contracted payers is recorded as an allowance to arrive at the reported net revenues. The expected revenues from non-contracted payers are based on the historical collection experience of each payer or payer group, as appropriate. The Company records revenues from patient pay tests net of a large discount and as a result recognizes minimal revenue on those tests. The Company regularly reviews its historical collection experience for non-contracted payers and adjusts its expected revenues for current and subsequent periods accordingly. The table below shows the adjustments made to gross service revenues to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended March 31, 2017 2016 Gross service revenues $ 83,938 $ 132,720 Total contractual adjustments and discounts (22,262 ) (73,016 ) Net revenues $ 61,676 $ 59,704

Equity

Equity	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Equity	Note H — Equity A summary of the stock option activity under the Company’s plans for the three months ended March 31, 2017 is as follows: Number of Weighted average shares exercise price Options outstanding at December 31, 2016 5,136,110 $ 5.76 Options granted 124,998 8.52 Less: Options exercised 210,652 2.23 Options canceled or expired 42,015 1.71 Options outstanding at March 31, 2017 5,008,441 5.99 Exercisable at March 31, 2017 1,202,639 4.77 Of the 5,008,441 outstanding options at March 31, 2017, 980,834 were variable accounted stock options issued to non-employees of the Company of which 161,667 options were vested and 819,167 options were unvested as of March 31, 2017. The fair value of each stock option award granted during the three months ended March 31, 2017 was estimated as of the grant date using a trinomial lattice model with the following weighted average assumptions: Three Months Ended March 31, 2017 Expected term (in years) 3.0 - 4.0 Risk-free interest rate (%) 1.3% Expected volatility (%) 47.6% - 53.0% Dividend yield (%) 0.0% Weighted average fair value/share at grant date $ 2.86 As of March 31, 2017, there was approximately $5.4 million of unrecognized share based compensation expense related to stock options that will be recognized over a weighted-average period of approximately 1.2 years. This includes approximately $917,000 in unrecognized expense related to the 819,167 shares of unvested variable accounted for stock options subject to fair value adjustment at the end of each reporting period based on changes in the Company’s stock price. Stock based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows (in thousands): Three Months Ended March 31, 2017 2016 Research and development expense $ 43 $ (9 ) General and administrative expense 1,087 796 Total stock based compensation expense $ 1,130 $ 787 Stock based compensation recorded in research and development relates to unvested options granted to a non-employee. Common Stock Warrants A summary of the warrant activity for the three months ended March 31, 2017 is as follows: Number of Weighted average shares exercise price Warrants outstanding at December 31, 2015 450,000 $ 1.50 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at March 31, 2017 450,000 1.50 Exercisable at March 31, 2017 450,000 1.50 During the three months ended March 31, 2017, we recorded $0 of warrant compensation expense and during the three months ended March 31, 2016, we recorded $(84,000) of warrant compensation gain, respectively. Warrant expense (gain) for the periods presented is recorded in research and development as the expense related to unvested performance based warrants granted to a non-employee. As of March 31, 2017 all warrants are fully vested.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments	Note I — Commitments During the three months ended March 31, 2017, the Company entered into leases for approximately $1.9 million in laboratory and computer equipment. These leases have 36 month terms, a $1.00 buyout option at the end of the terms and interest rates ranging from 4.5% to 6.2%. The Company accounted for these lease agreements as capital leases.

Other Related Party Transaction

Other Related Party Transaction	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Other Related Party Transaction	Note J— Other Related Party Transaction During each of the three month periods ended March 31, 2017 and 2016, Steven C. Jones was an officer, director and shareholder of the Company. Mr. Jones earned approximately $66,000 for consulting work performed in connection with his duties as Executive Vice President during each of the three months ended March 31, 2017 and 2016. Mr. Jones also received approximately $85,000 and $79,000 during each of the three months ended March 31, 2017 and 2016 as payment of his annual bonus compensation for the previous fiscal years. In addition, as compensation for his services on the Board, Mr. Jones earned $12,500 and $0 for the three months ended March 31, 2017 and 2016.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Event	Note K — Subsequent Event On April 28, 2017, the Compensation Committee of the Board of Directors granted 1,430,000 options to certain executive officers and key employees of the Company. The options were granted at a price of $7.52 per share and had a weighted average fair market value of $2.76 per option for a total fair market value of $3.9 million. We expect our stock option compensation expense to increase by approximately $1.7 million, $1.6 million, $708,000, and $161,000 in the years ended December 31, 2017, 2018, 2019 and 2020, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the three month period ended March 31, 2017 and for the year ended December 31, 2016 are as follows (in thousands): March 31, December 31, 2017 2016 Balance as of January 1 $ 147,019 $ 147,019 Goodwill acquired during the period - - Balance at end of period $ 147,019 $ 147,019
Classes of Intangible Assets	Intangible assets as of March 31, 2017 and December 31, 2016 consisted of the following (in thousands): March 31, 2017 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 1,883 $ 1,117 Customer Relationships 156 - 180 months 81,000 6,778 74,222 Total $ 84,000 $ 8,661 $ 75,339 December 31, 2016 Amortization Period Cost Accumulated Amortization Net Trade Name 24 months $ 3,000 $ 1,508 $ 1,492 Customer Relationships 156 - 180 months 81,000 5,428 75,572 Total $ 84,000 $ 6,936 $ 77,064
Estimated Amortization Expense	The estimated amortization expense related to amortizable intangible assets for each of the five succeeding fiscal years and thereafter as of March 31, 2017 is as follows (in thousands): Year Ending March 31, Remainder of 2017 $ 5,167 2018 5,400 2019 5,400 2020 5,400 2021 5,400 Thereafter 48,572 Total $ 75,339

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Summary of Long Term Debt	The following table summarizes the long term debt at March 31, 2017 and December 31, 2016 (in thousands): March 31, 2017 December 31, 2016 Term Loan Facility $ 74,063 $ 75,000 Revolving Credit Facility 27,900 22,900 Capital leases/loans 11,105 10,471 Total Debt 113,068 108,371 Less: Debt issuance costs (2,080 ) (2,202 ) Less: Current portion of long-term debt (8,834 ) (8,733 ) Total Long-Term Debt, net $ 102,154 $ 97,436
Summary of Maturities of Long-Term Debt	Maturities of long-term debt at March 31, 2017 are summarized as follows (in thousands): Debt Capital Lease Obligations and Car Loans Total Long Term Debt Remainder of 2017 $ 2,812 $ 5,922 $ 8,734 2018 3,750 4,362 8,112 2019 5,625 2,764 8,389 2020 5,625 335 5,960 2021 84,151 - 84,151 101,963 13,383 115,346 Less: Interest on capital leases - (2,278 ) (2,278 ) 101,963 11,105 113,068 Less: Current portion of long-term debt (3,750 ) (5,084 ) (8,834 ) Less: Debt issuance costs (2,080 ) - (2,080 ) Long-term debt, net $ 96,133 $ 6,021 $ 102,154

Revenue Recognition and Contr19

Revenue Recognition and Contractual Adjustments (Tables)	3 Months Ended
	Mar. 31, 2017
Revenue Recognition [Abstract]
Adjustment of Transactions Revenue	The table below shows the adjustments made to gross service revenues to arrive at net revenues (in thousands), the amount reported on our statements of operations. Three Months Ended March 31, 2017 2016 Gross service revenues $ 83,938 $ 132,720 Total contractual adjustments and discounts (22,262 ) (73,016 ) Net revenues $ 61,676 $ 59,704

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Summary of Stock Option Activity	A summary of the stock option activity under the Company’s plans for the three months ended March 31, 2017 is as follows: Number of Weighted average shares exercise price Options outstanding at December 31, 2016 5,136,110 $ 5.76 Options granted 124,998 8.52 Less: Options exercised 210,652 2.23 Options canceled or expired 42,015 1.71 Options outstanding at March 31, 2017 5,008,441 5.99 Exercisable at March 31, 2017 1,202,639 4.77
Fair Value of Each Stock Option Award Granted	The fair value of each stock option award granted during the three months ended March 31, 2017 was estimated as of the grant date using a trinomial lattice model with the following weighted average assumptions: Three Months Ended March 31, 2017 Expected term (in years) 3.0 - 4.0 Risk-free interest rate (%) 1.3% Expected volatility (%) 47.6% - 53.0% Dividend yield (%) 0.0% Weighted average fair value/share at grant date $ 2.86
Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations	Stock based compensation expense recognized for stock options and restricted stock and included in the consolidated statements of operations was allocated as follows (in thousands): Three Months Ended March 31, 2017 2016 Research and development expense $ 43 $ (9 ) General and administrative expense 1,087 796 Total stock based compensation expense $ 1,130 $ 787
Summary of Warrant Activity	Common Stock Warrants A summary of the warrant activity for the three months ended March 31, 2017 is as follows: Number of Weighted average shares exercise price Warrants outstanding at December 31, 2015 450,000 $ 1.50 Warrants granted — — Less: Warrants exercised — — Warrants canceled or expired — — Warrants outstanding at March 31, 2017 450,000 1.50 Exercisable at March 31, 2017 450,000 1.50

Nature of Business and Basis 21

Nature of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017SegmentCustomer	Mar. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of reportable segments | Segment	1
Percentage of consolidated assets, net revenues and net income of reportable segment	100.00%	100.00%
Number of primary types of customers | Customer	2

Recently Adopted and Issued A22

Recently Adopted and Issued Accounting Guidance - Additional Information (Detail) - Accounting Standards Update 2016-09 [Member] - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Cumulative-effect adjustment to retained earnings	$ 6,600,000
Excess tax benefits as cash flows from operating activities		$ 0

Goodwill and Intangible Asset23

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	$ 147,019		$ 147,019	$ 147,019
Amortization of intangibles	$ 1,725	$ 2,026

Goodwill and Intangible Asset24

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Balance as of January 1	$ 147,019	$ 147,019
Balance at end of period	$ 147,019	$ 147,019

Goodwill and Intangible Asset25

Goodwill and Intangible Assets - Classes of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 84,000	$ 84,000
Accumulated Amortization	8,661	6,936
Total	$ 75,339	$ 77,064
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	24 months	24 months
Cost	$ 3,000	$ 3,000
Accumulated Amortization	1,883	1,508
Total	1,117	1,492
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	81,000	81,000
Accumulated Amortization	6,778	5,428
Total	$ 74,222	$ 75,572
Minimum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	156 months	156 months
Maximum [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period	180 months	180 months

Goodwill and Intangible Asset26

Goodwill and Intangible Assets - Estimated Amortization Expense (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 5,167
2,018	5,400
2,019	5,400
2,020	5,400
2,021	5,400
Thereafter	48,572
Total	$ 75,339	$ 77,064

Debt - Summary of Long Term Deb

Debt - Summary of Long Term Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long-Term Debt	$ 101,963
Capital leases/loans	11,105	$ 10,471
Total Debt	113,068	108,371
Less: Debt issuance costs	(2,080)	(2,202)
Less: Current portion of long-term debt	(8,834)	(8,733)
Total Long-Term Debt, net	102,154	97,436
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-Term Debt	74,063	75,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Long-Term Debt	$ 27,900	$ 22,900

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Dec. 22, 2016	Mar. 31, 2017	Dec. 31, 2016
Line Of Credit Facility [Line Items]
Long-term outstanding borrowings		$ 26,860,000	$ 21,799,000
Capital Leases [Member]
Line Of Credit Facility [Line Items]
Debt instrument, Weighted average interest rates		5.64%
Term Loan [Member]
Line Of Credit Facility [Line Items]
Debt Instrument, maximum borrowing capacity	$ 75,000,000
Line of credit facility incremental borrowing capacity	$ 50,000,000
Current outstanding borrowings		$ 3,800,000	3,800,000
Long-term outstanding borrowings		69,300,000	70,100,000
Unamortized transaction costs		$ 1,000,000	1,100,000
Interest rate description		(1) the Adjusted LIBOR rate for the relevant interest period, (2) an alternate base rate determined by reference to the greatest of (a) the prime lending rate of Regions, (b) the federal funds rate for the relevant interest period plus 0.5% per annum and (c) the one month LIBOR rate plus 1% per annum, or (3) a combination of (1) and (2). The applicable margin will range from 2.25% to 3.50% for LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories’ consolidated leverage ratio (as defined in the Credit Agreement). Interest on borrowings under the Revolving Credit Facility is payable on the last day of each month, in the case of each base rate loan, and on the last day of each interest period (but no less frequently than every three months), in the case of Adjusted LIBOR loans. The Company entered into an interest rate swap agreement to hedge against changes in the variable rate of a portion of this debt.
Debt instrument, maturity date	Dec. 21, 2021
Debt instrument prepayment description		The Credit Agreement requires NeoGenomics Laboratories to mandatorily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility with (i) 100% of net cash proceeds from certain sales and dispositions, subject to certain reinvestment rights, (ii) 100% of net cash proceeds from certain issuances or incurrences of additional debt, (iii) beginning with the fiscal year ending December 31, 2017, 50% of excess cash flow (as defined), subject to a step down to 0% of excess cash flow if NeoGenomics Laboratories’ consolidated leverage ratio is no greater than 2.75:1.0 and (iv) 100% of net cash proceeds from issuances of permitted equity securities by NeoGenomics Laboratories made in order to cure a failure to comply with the financial covenants. NeoGenomics Laboratories is permitted to voluntarily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility at any time without penalty.
Percentage of net cash proceeds for mandatory prepayment under facility	100.00%
Percentage of net cash proceeds from issuances or incurrence of additional debt for mandatory prepayment under facility	100.00%
Leverage ratio used to determine mandatory prepayments under credit facility	275.00%
Percentage of net cash proceeds from issuances of permitted equity securities to be used for mandatory prepayment under facility	100.00%
Term Loan [Member] | Leverage Ratio Greater Than Or Equal To 2.75:1.0 [Member]
Line Of Credit Facility [Line Items]
Percentage of excess cash flow to be used for mandatory prepayments under facility	50.00%
Term Loan [Member] | Leverage Ratio Less Than 2.75:1.0 [Member]
Line Of Credit Facility [Line Items]
Percentage of excess cash flow to be used for mandatory prepayments under facility	0.00%
Term Loan [Member] | Federal Funds Rate Plus [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	0.50%
Term Loan [Member] | LIBOR Rate Plus [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	1.00%
Term Loan [Member] | LIBOR Rate Plus [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument applicable margin	2.25%
Term Loan [Member] | LIBOR Rate Plus [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument applicable margin	3.50%
Term Loan [Member] | Base Rate [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument applicable margin	1.25%
Term Loan [Member] | Base Rate [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument applicable margin	2.50%
Auto Loans [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument, Term		36 months
Debt instrument, Interest rate		0.00%
Auto Loans [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument, Term		60 months
Debt instrument, Interest rate		5.20%
Revolving Credit Facility [Member]
Line Of Credit Facility [Line Items]
Debt instrument, maturity date	Dec. 21, 2021
Percentage of net cash proceeds for mandatory prepayment under facility	100.00%
Percentage of net cash proceeds from issuances or incurrence of additional debt for mandatory prepayment under facility	100.00%
Leverage ratio used to determine mandatory prepayments under credit facility	275.00%
Percentage of net cash proceeds from issuances of permitted equity securities to be used for mandatory prepayment under facility	100.00%
Line of credit facility maximum borrowing capacity	$ 75,000,000
Long-term outstanding borrowings		$ 26,900,000	21,800,000
Unamortized transaction costs		$ 1,000,000	$ 1,100,000
Line of credit facility swingline sublimit	$ 10,000,000
Debt instrument description		(1) the Adjusted LIBOR rate for the relevant interest period, (2) an alternate base rate determined by reference to the greatest of (a) the prime lending rate of Regions, (b) the federal funds rate for the relevant interest period plus 0.5% per annum and (c) the one month LIBOR rate plus 1% per annum, or (3) a combination of (1) and (2). The applicable margin will range from 2.25% to 3.50% for Adjusted LIBOR loans and 1.25% to 2.50% for base rate loans, in each case based on NeoGenomics Laboratories’ consolidated leverage ratio.
Debt instrument prepayment description		The Credit Agreement requires NeoGenomics Laboratories to mandatorily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility with (i) 100% of net cash proceeds from certain sales and dispositions, subject to certain reinvestment rights, (ii) 100% of net cash proceeds from certain issuances or incurrences of additional debt, (iii) beginning with the fiscal year ending December 31, 2017, 50% of excess cash flow (minus certain specified other payments), subject to a step down to 0% of excess cash flow if NeoGenomics Laboratories’ consolidated leverage ratio is no greater than 2.75:1.0 and (iv) 100% of net cash proceeds from issuances of permitted equity securities by NeoGenomics Laboratories made in order to cure a failure to comply with the financial covenants. NeoGenomics Laboratories is permitted to voluntarily prepay the Term Loan Facility and amounts borrowed under the Revolving Credit Facility at any time without penalty, subject to customary “breakage” costs with respect to prepayments of Adjusted LIBOR rate loans made on a day other than the last day of any applicable interest period.
Revolving Credit Facility [Member] | Leverage Ratio Greater Than Or Equal To 2.75:1.0 [Member]
Line Of Credit Facility [Line Items]
Percentage of excess cash flow to be used for mandatory prepayments under facility	50.00%
Revolving Credit Facility [Member] | Leverage Ratio Less Than 2.75:1.0 [Member]
Line Of Credit Facility [Line Items]
Percentage of excess cash flow to be used for mandatory prepayments under facility	0.00%
Revolving Credit Facility [Member] | Federal Funds Rate Plus [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	0.50%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	1.00%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	2.25%
Revolving Credit Facility [Member] | LIBOR Rate Plus [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	3.50%
Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	1.25%
Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Line Of Credit Facility [Line Items]
Debt instrument variable interest rate	2.50%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Long Term Debt (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Remainder of 2017	$ 2,812
2,018	3,750
2,019	5,625
2,020	5,625
2,021	84,151
Long-term Debt	101,963
Long-Term Debt	101,963
Less: Current portion of long-term debt	(3,750)
Less: Debt issuance costs	(2,080)	$ (2,202)
Long-term debt, net	96,133
Remainder of 2017	5,922
2,018	4,362
2,019	2,764
2,020	335
Capital Lease Obligations	13,383
Less: Interest on capital leases	(2,278)
Capital Lease Obligations	11,105	10,471
Less: Current portion of long-term debt	(5,084)
Long-term debt, net	6,021
Remainder of 2017	8,734
2,018	8,112
2,019	8,389
2,020	5,960
2,021	84,151
Long-term Debt and Capital Lease Obligations	115,346
Less: Interest on capital leases	(2,278)
Debt and Capital Lease Obligations	113,068	108,371
Less: Current portion of long-term debt	(8,834)	(8,733)
Total Long-Term Debt, net	$ 102,154	$ 97,436

Derivative Instruments and He30

Derivative Instruments and Hedging Activities - Additional Information (Details) - Interest Rate Swaps [Member] - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Derivative [Line Items]
Fixed rate of interest percentage payment	1.59%
Effective date	Dec. 30, 2016
Termination date	Dec. 31, 2019
Total notional amount	$ 50,000,000	$ 50,000,000
Fair value of derivative instrument	$ 0	$ 0

Class A Redeemable Convertibl31

Class A Redeemable Convertible Preferred Stock - Additional Information (Detail) - USD ($)	Dec. 22, 2016	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 30, 2015
Temporary Equity [Line Items]
Temporary equity, shares issued		6,600,000		6,600,000
Temporary equity, face value		$ 0.001		$ 0.001
Temporary equity, shares outstanding		6,600,000		6,600,000
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Temporary equity, shares issued					14,666,667
Temporary equity, face value					$ 7.50
Temporary equity, liquidation value		$ 49,500			$ 110,000,000
Temporary equity, liquidation description		During the first year, the Series A Preferred Stock had a liquidation value of $100 million if the shares were redeemed prior to December 29, 2016.
Temporary equity, liquidation at redemption		$ 100,000,000
Temporary equity, shares redemption	8,066,667
Temporary equity, redemption amount	$ 55,000,000
Temporary equity, redemption per share	$ 6.8181825
Redemption Discount	9.0909%
Temporary equity, shares outstanding	6,600,000
Temporary equity, carrying amount		25,439,000,000		$ 22,873,000,000
Temporary equity, accrual of deemed dividends		894,000
Temporary equity, accretion of beneficial conversion feature		1,700,000
Temporary equity, fair value		$ 32,940			$ 73,200,000
Temporary equity issued, price per share		$ 4.99			$ 4.99
Temporary equity issue discount		$ 16,560			$ 36,800,000
Temporary equity, value of beneficial conversion feature		20,100,000			$ 44,700,000
Temporary equity, recognized amount of beneficial conversion feature		1,700,000
Series A Redeemable Convertible Preferred Stock [Member] | Payment In Kind Period Two [Member]
Temporary Equity [Line Items]
Temporary equity, fair value		49,500,000
Temporary equity issue discount		$ 201,000
Series A Redeemable Convertible Preferred Stock [Member] | Payment In Kind Period Two [Member] | Scenario, Forecast [Member]
Temporary Equity [Line Items]
Temporary equity, face value			$ 7.50
Additional preferred stock to be issued			264,000
Payment-in-kind Dividend Rate per Annum in Effect			4.00%

Revenue Recognition and Contr32

Revenue Recognition and Contractual Adjustments - Adjustment of Transactions Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue Recognition [Abstract]
Gross service revenues	$ 83,938	$ 132,720
Total contractual adjustments and discounts	(22,262)	(73,016)
Total Revenue	$ 61,676	$ 59,704

Equity - Summary of Stock Optio

Equity - Summary of Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Equity [Abstract]
Stock options, beginning balance | shares	5,136,110
Stock options, granted | shares	124,998
Stock options, exercised | shares	210,652
Stock options, canceled or expired | shares	42,015
Stock options, ending balance | shares	5,008,441
Stock options, exercisable, ending balance | shares	1,202,639
Weighted average exercise price, beginning balance | $ / shares	$ 5.76
Weighted average exercise price, granted | $ / shares	8.52
Weighted average exercise price, exercised | $ / shares	2.23
Weighted average exercise price, canceled or expired | $ / shares	1.71
Weighted average exercise price, ending balance | $ / shares	5.99
Weighted average exercise price, exercisable, ending balance | $ / shares	$ 4.77

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option outstanding	5,008,441		5,136,110
Stock options, granted	124,998
Unrecognized stock-based compensation cost	$ 5,400,000
Unrecognized share-based compensation expense, weighted-average recognition period	1 year 2 months 12 days
Stock compensation expense (gain)	$ 1,130,000	$ 787,000
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense (gain)	43,000	(9,000)
Research And Development Expense [Member] | Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense (gain)	$ 0	$ (84,000)
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted	980,834
Stock option vested	161,667
Stock option unvested	819,167
Unrecognized stock-based compensation cost	$ 917,000

Equity - Fair Value of Each Sto

Equity - Fair Value of Each Stock Option Award Granted (Detail)	3 Months Ended
	Mar. 31, 2017$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (%)	1.30%
Dividend yield (%)	0.00%
Weighted average fair value/share at grant date	$ 2.86
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	3 years
Expected volatility (%)	47.60%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	4 years
Expected volatility (%)	53.00%

Equity - Summary of Stock-Based

Equity - Summary of Stock-Based Compensation Expense Recognized for Stock Options and Restricted Stock Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,130	$ 787
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	43	(9)
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 1,087	$ 796

Equity - Summary of Warrant Act

Equity - Summary of Warrant Activity (Detail) - Warrant [Member]	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, beginning balance | shares	450,000
Warrants, granted | shares	0
Warrants, exercised | shares	0
Warrants, canceled or expired | shares	0
Warrants outstanding, ending balance | shares	450,000
Warrants exercisable, ending balance | shares	450,000
Weighted average exercise price, warrants outstanding, beginning balance | $ / shares	$ 1.50
Weighted average exercise price, warrants granted | $ / shares	0
Weighted average exercise price, warrants exercised | $ / shares	0
Weighted average exercise price, warrants canceled or expired | $ / shares	0
Weighted average exercise price, warrants outstanding, ending balance | $ / shares	1.50
Weighted average exercise price, warrants exercisable, ending balance | $ / shares	$ 1.50

Commitments - Additional Inform

Commitments - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Contractual Obligation [Line Items]
Capital lease obligation amount	$ 1,898,000	$ 173,000
Laboratory and Computer Equipment [Member]
Contractual Obligation [Line Items]
Capital lease obligation amount	$ 1,900,000
Lease term period	36 months
Buyout option	$ 1
Minimum [Member] | Laboratory and Computer Equipment [Member]
Contractual Obligation [Line Items]
Interest rate	4.50%
Maximum [Member] | Laboratory and Computer Equipment [Member]
Contractual Obligation [Line Items]
Interest rate	6.20%

Other Related Party Transacti39

Other Related Party Transaction - Additional Information (Detail) - Executive Vice President [Member] - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Related Party Transaction [Line Items]
Fees for consulting work performed	$ 66,000	$ 66,000
Payment of annual bonus compensation	85,000	79,000
Compensation for services on the board	$ 12,500	$ 0

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($)	Apr. 28, 2017	Mar. 31, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Options, grant date price		$ 8.52
Scenario, Forecast [Member] | 2017 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase						$ 1,700,000
Scenario, Forecast [Member] | 2018 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase					$ 1,600,000
Scenario, Forecast [Member] | 2019 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase				$ 708,000
Scenario, Forecast [Member] | 2020 [Member]
Subsequent Event [Line Items]
Expected stock option compensation expense increase			$ 161,000
Subsequent Event [Member] | Certain Executive Officers and Key Employees [Member]
Subsequent Event [Line Items]
Options, number granted	1,430,000
Options, grant date price	$ 7.52
Options, weighted average fair market value	$ 2.76
Total fair value of options granted	$ 3,900,000